Revive Therapeutics

Revive Therapeutics (RVVTF, RVV): Updates and News Archive.

Recent Headlines (See FDA Filing Submission at Bottom) LIVE QUOTE

Track Record

Click to open 21 clients up over $100 million, 13 clients up over ten-fold in value.
CPRE Networks

Adding VYRE Network (CAPV) to the Watch List.

Look What We Found. Our First Internet Play in Ages, And It's a Doozy. We would categorize this...
omniq

OMNIQ (OMQS) Graduates to NASDAQ. And Three Wall Street Research Reports Follow.

Wall Street Brokerage Price Target Estimates of $15 - $18 Per Share. Without disrupting legacy sales - CEO Shai...
Ehave, Psychedelic Stock Review

Report: Ehave Inc (EHVVF) Our Favorite Psychedelic Company

WE LOOKED FAR AND WIDE TO FIND OUR FAVORITE What exactly is a favorite? First...

Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.

Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022. CITIUS NEWS ARCHIVE
Hea;thLynked, Biotech Stock Review

Up 191%, HealthLynked (HLYK) Reporting Decent Numbers.

Up as much as 417% from where we added it to the Watch List, the Company continues to report increasing revenues while...
@alanliverin

Bitcoin $30,000. Time to Bargain Hunt? Read This First.

The Bit Short: Inside Crypto’s Doomsday Machine Scary article on Tether/Bitcoin posted on...
Internet Stock Review, Draganfly

Meet Draganfly (DFLYF) the Tesla of Drones.

A New Leader In The Drone Industry Emerges US Government Bans Chinese Drones Surprise...
CB Scientific, Biotech Stock Review, Telehealth

Report: My-Cam™ and My-Cardia™ the Ultimate ‘Any-Doctor-Anywhere’ Telehealth Monitoring Application.

New and Updated Report on CB Scientific (CBSC) $1.05. Revolutionary Any-Doctor-Any Where, at Home Heart Rate Monitor, can...

Latest article

Smart for Life (SMFL) Capitulates?

We Are Long Term Bullish on Smart for Life. After a Volatile Post IPO Trading, we may Have Seen the Bottom....

Althira (ATHA) $2.50, is Latest Alzheimer’s Trial Victim. Down 70%

Nearly 100 Alzheimer’s programs have failed in the past decade. Biotech investors should study or at least become...

Novogratz Remains Steadfast on Crypto, Says Wait Until Next Year (Bloomberg)

Great call. This was actually from Late 2018. (Bloomberg) — Billionaire investor Michael Novogratz is resolute when it...